Literature DB >> 30196156

Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function.

Suzanne R Sharpton1, Veeral Ajmera2, Rohit Loomba3.   

Abstract

The gut microbiome, a diverse microbial community in the gastrointestinal tract, plays a pivotal role in the maintenance of health. The gut microbiome metabolizes dietary and host-derived molecules to produce bioactive metabolites, which have a wide array of effects on host metabolism and immunity. 'Dysbiosis' of the gut microbiome, commonly considered as perturbation of microbiome diversity and composition, has been associated with intestinal and extra-intestinal diseases, including nonalcoholic fatty liver disease (NAFLD). A number of endogenous and exogenous factors, such as nutritional intake and xenobiotic exposure, can alter the gut microbiome. We will review the evolving methods for studying the gut microbiome and how these profiling techniques have been utilized to further our understanding of the gut microbial community composition and functional potential in the clinical spectrum of NAFLD. We will highlight microbiome-host interactions that may contribute to the pathogenesis of NAFLD, with a primary focus on mechanisms related to the metabolic output of the gut microbiome. Finally, we will discuss potential therapeutic implications of the gut microbiome in NAFLD.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Microbiota; Nonalcoholic Fatty Liver

Year:  2018        PMID: 30196156      PMCID: PMC6314895          DOI: 10.1016/j.cgh.2018.08.065

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  77 in total

1.  THE PREVENTION BY CHOLINE OF LIVER CIRRHOSIS IN RATS ON HIGH FAT, LOW PROTEIN DIETS.

Authors:  H Blumberg; E V McCollum
Journal:  Science       Date:  1941-06-20       Impact factor: 47.728

2.  Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin.

Authors:  Ina Bergheim; Synia Weber; Miriam Vos; Sigrid Krämer; Valentina Volynets; Seline Kaserouni; Craig J McClain; Stephan C Bischoff
Journal:  J Hepatol       Date:  2008-03-14       Impact factor: 25.083

3.  Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH.

Authors:  Lixin Zhu; Susan S Baker; Chelsea Gill; Wensheng Liu; Razan Alkhouri; Robert D Baker; Steven R Gill
Journal:  Hepatology       Date:  2013-01-08       Impact factor: 17.425

4.  Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.

Authors:  Rohit Loomba; Victor Seguritan; Weizhong Li; Tao Long; Niels Klitgord; Archana Bhatt; Parambir Singh Dulai; Cyrielle Caussy; Richele Bettencourt; Sarah K Highlander; Marcus B Jones; Claude B Sirlin; Bernd Schnabl; Lauren Brinkac; Nicholas Schork; Chi-Hua Chen; David A Brenner; William Biggs; Shibu Yooseph; J Craig Venter; Karen E Nelson
Journal:  Cell Metab       Date:  2017-05-02       Impact factor: 27.287

5.  Inulin-type fructans modulate intestinal Bifidobacterium species populations and decrease fecal short-chain fatty acids in obese women.

Authors:  Nuria Salazar; Evelyne M Dewulf; Audrey M Neyrinck; Laure B Bindels; Patrice D Cani; Jacques Mahillon; Willem M de Vos; Jean-Paul Thissen; Miguel Gueimonde; Clara G de Los Reyes-Gavilán; Nathalie M Delzenne
Journal:  Clin Nutr       Date:  2014-06-11       Impact factor: 7.324

6.  Microbiota and SCFA in lean and overweight healthy subjects.

Authors:  Andreas Schwiertz; David Taras; Klaus Schäfer; Silvia Beijer; Nicolaas A Bos; Christiane Donus; Philip D Hardt
Journal:  Obesity (Silver Spring)       Date:  2009-06-04       Impact factor: 5.002

7.  Biomarkers for type 2 diabetes and impaired fasting glucose using a nontargeted metabolomics approach.

Authors:  Cristina Menni; Eric Fauman; Idil Erte; John R B Perry; Gabi Kastenmüller; So-Youn Shin; Ann-Kristin Petersen; Craig Hyde; Maria Psatha; Kirsten J Ward; Wei Yuan; Mike Milburn; Colin N A Palmer; Timothy M Frayling; Jeff Trimmer; Jordana T Bell; Christian Gieger; Rob P Mohney; Mary Julia Brosnan; Karsten Suhre; Nicole Soranzo; Tim D Spector
Journal:  Diabetes       Date:  2013-07-24       Impact factor: 9.461

8.  Proton pump inhibitors alter the composition of the gut microbiota.

Authors:  Matthew A Jackson; Julia K Goodrich; Maria-Emanuela Maxan; Daniel E Freedberg; Julian A Abrams; Angela C Poole; Jessica L Sutter; Daphne Welter; Ruth E Ley; Jordana T Bell; Tim D Spector; Claire J Steves
Journal:  Gut       Date:  2015-12-30       Impact factor: 23.059

Review 9.  Intestinal Short Chain Fatty Acids and their Link with Diet and Human Health.

Authors:  David Ríos-Covián; Patricia Ruas-Madiedo; Abelardo Margolles; Miguel Gueimonde; Clara G de Los Reyes-Gavilán; Nuria Salazar
Journal:  Front Microbiol       Date:  2016-02-17       Impact factor: 5.640

Review 10.  Current understanding of the human microbiome.

Authors:  Jack A Gilbert; Martin J Blaser; J Gregory Caporaso; Janet K Jansson; Susan V Lynch; Rob Knight
Journal:  Nat Med       Date:  2018-04-10       Impact factor: 53.440

View more
  37 in total

Review 1.  Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps.

Authors:  Amedeo Lonardo; Fabio Nascimbeni; Stefano Ballestri; DeLisa Fairweather; Sanda Win; Tin A Than; Manal F Abdelmalek; Ayako Suzuki
Journal:  Hepatology       Date:  2019-09-23       Impact factor: 17.425

2.  Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression.

Authors:  Suzanne R Sharpton; Bharat Maraj; Emily Harding-Theobald; Eric Vittinghoff; Norah A Terrault
Journal:  Am J Clin Nutr       Date:  2019-07-01       Impact factor: 7.045

Review 3.  Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives.

Authors:  Juan P Arab; Marco Arrese; Vijay H Shah
Journal:  Hepatol Res       Date:  2020-01-13       Impact factor: 4.288

Review 4.  Microbiome Modulation in Liver Disease.

Authors:  Eamonn M M Quigley
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-11-06

5.  The Intestinal Microbiome, Plasma Metabolome, and Liver Transcriptome: A Conspiracy Driving Hepatic Steatosis.

Authors:  Wajahat Z Mehal; Rohit Loomba
Journal:  Hepatology       Date:  2019-04-11       Impact factor: 17.425

Review 6.  Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver?

Authors:  Tien S Dong; Jonathan P Jacobs
Journal:  Exp Biol Med (Maywood)       Date:  2019-03-14

Review 7.  Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.

Authors:  Judith Aron-Wisnewsky; Chloé Vigliotti; Julia Witjes; Phuong Le; Adriaan G Holleboom; Joanne Verheij; Max Nieuwdorp; Karine Clément
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-03-09       Impact factor: 46.802

8.  Characterization of the variability in the extent of nonalcoholic fatty liver induced by a high-fat diet in the genetically diverse Collaborative Cross mouse model.

Authors:  Aline de Conti; Volodymyr Tryndyak; Rose A Willett; Barbara Borowa-Mazgaj; Anna Watson; Ralph Patton; Sangeeta Khare; Levan Muskhelishvili; Greg R Olson; Mark I Avigan; Carl E Cerniglia; Sharon A Ross; Arun J Sanyal; Frederick A Beland; Ivan Rusyn; Igor P Pogribny
Journal:  FASEB J       Date:  2020-04-18       Impact factor: 5.191

9.  Nonalcoholic fatty liver disease as a risk factor for Clostridioides difficile infection.

Authors:  Neven Papić; Fabijan Jelovčić; Marko Karlović; Lorna Stemberger Marić; Adriana Vince
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-11-28       Impact factor: 3.267

10.  The Gut Microbiome and Xenobiotics: Identifying Knowledge Gaps.

Authors:  Vicki L Sutherland; Charlene A McQueen; Donna Mendrick; Donna Gulezian; Carl Cerniglia; Steven Foley; Sam Forry; Sangeeta Khare; Xue Liang; Jose E Manautou; Donald Tweedie; Howard Young; Alexander V Alekseyenko; Frank Burns; Rod Dietert; Alan Wilson; Connie Chen
Journal:  Toxicol Sci       Date:  2020-07-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.